Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 12 of 40 · 1917 articles
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...
The project targets a molecular regulator of tuft cells, which help control mucosal immune responses and have been linked to chronic gut inflammation such as ulcerative colitis. Discovering how OCA-T2 shapes tuft cell...
This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could...
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
The study links a traditional acupuncture-derived technique (ACE) to reduced colitis severity in rats and to modulation of the cGAS–STING immune pathway and macrophage marker profiles, suggesting a potential mechanistic...
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require...
The review suggests LJF contains compounds that may reduce intestinal inflammation, support gut barrier health, and influence microbiota—areas directly relevant to ulcerative colitis and colorectal cancer risk. However,...
Histology and endoscopy are both used to assess UC activity; knowing which histologic score is reliable and practical helps clinicians and pathologists standardize monitoring and may streamline reporting in routine care.
The study suggests ED presentation symptoms predict admission differently in UC versus CD, which could affect triage and short-term risk assessment for IBD patients. Knowing which symptoms are stronger predictors by...
The study links IRF5 to worse intestinal inflammation in UC and shows that reducing IRF5 activity lessens disease in a mouse model, suggesting IRF5 could be a future therapeutic target or biomarker.
The study presents a new inflammation-responsive oral delivery system designed to concentrate antioxidant and anti-inflammatory activity in the colon, which could—if translated safely to humans—offer a way to treat...
Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive...
The exposome perspective emphasizes that many non-genetic, potentially modifiable environmental factors likely influence IBD risk. Understanding these factors could help guide prevention research and public-health...
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
The study suggests some autoimmune diseases common in IBD patients—ulcerative colitis and primary sclerosing cholangitis—may be genetically linked to higher pancreatitis risk. That could help researchers understand...
This preclinical study links NOX1/4 and NLRP3 pathways to ferroptosis and iron metabolism in a mouse colitis model, highlighting potential mechanistic targets that could inform future precision therapies for ulcerative...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Journal of Crohn's & colitis.
This study suggests routine restriction of oral intake during IBD flares (without obstruction/abscess/fistula) is common but not linked to better short-term outcomes, so unnecessary fasting may be avoidable for many...
S1PR1 drugs (S1P modulators) are an important drug class for IBD; a selective S1PR1 agonist with less S1PR3 activity could mean fewer heart-related side effects. This preclinical work highlights a possible new candidate...
The review describes a novel preclinical approach—catalytic nanozymes—that aims to reduce oxidative stress and re-balance immune responses in ulcerative colitis, which could eventually lead to new treatments for patients...
The report identifies rare, East-Asian–enriched genetic variants that appear to affect age at IBD diagnosis and disease progression, which could help explain clinical differences in Korean patients and guide future...
A new fluorescent probe designed from bile acids may help image inflammation and has shown anti-inflammatory/antioxidant activity in cell studies relevant to ulcerative colitis, which could inform future diagnostic or...
Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small...
Older adults with IBD face tradeoffs between effectiveness and safety of advanced therapies; this study aims to identify immune‑aging and frailty markers that might predict who is more likely to benefit without serious...
Tofacitinib has been linked to increased risk of venous thromboembolism in other post‑marketing safety studies; this trial examines coagulation and platelet effects in UC patients, which could help clarify mechanisms and...
This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Colorectal cancer, and Diet and lifestyle. The original article is from Food science &...
Automated analysis of full-length endoscopy videos could standardise assessment of UC activity, identify spatial patterns of inflammation, and better estimate histological healing—information that may influence treatment...
The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.
Dietary strategies like UCED aim to modify the gut microbiome and inflammation, which could help people with ulcerative colitis who have incomplete symptom control on medication. Patients often want nonpharmacologic...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Materials Today Bio.
The findings identify a natural microbial metabolite (urolithin A) that appears to strengthen the intestinal barrier and aid tissue repair via a specific receptor and inflammasome pathway, suggesting new, more targeted...
Dietary patterns may help reduce symptoms and improve quality of life for many people with ulcerative colitis and could influence inflammatory biomarkers and the gut microbiome, offering a nonpharmacologic adjunct to...
The article highlights a natural gut-microbe product (urolithin A) that may help repair the intestinal lining by activating a protective molecular pathway.
A blood biomarker that tracks both symptoms and endoscopic inflammation could help with noninvasive monitoring of ulcerative colitis activity and reduce reliance on invasive procedures if validated.
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...
Long-term safety information matters for people with ulcerative colitis considering or already taking filgotinib, because LTE studies track adverse events and lab changes over years. Findings from such a study can...
Patients and surgeons weighing robotic versus laparoscopic IPAA for ulcerative colitis may care because the study suggests similar short-term complication rates between approaches in this cohort, which could inform...
Genetic evidence that PBC may causally influence risk of IBD (and UC specifically) could help explain observed co-occurrence of these autoimmune diseases and point researchers toward shared pathways worth studying.
A new small molecule that blocks the NLRP3 inflammasome via ProRS could point to future drug strategies for ulcerative colitis — a pathway involved in intestinal inflammation that matters to people with IBD. This is...
The study introduces a colon-targeted EGCG delivery system that reduced inflammation and improved microbial and metabolic markers in a mouse model of UC, suggesting a potential new therapeutic approach worth further...
People with ulcerative colitis can rarely develop visceral pyoderma gangrenosum that mimics infection (for example, a splenic abscess). Recognizing this can prevent unnecessary invasive procedures and guide appropriate...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.
An orally dosed, gut-targeted PDE4 prodrug entering Phase 2 could offer a new locally acting anti-inflammatory option for people with UC or Crohn’s, potentially with fewer systemic side effects than older PDE4 drugs.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Frontiers in...
Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...
